October 22, 2020

An IPO Alternative: Life Sciences Reverse Merger


Many companies are seeking alternatives to the traditional IPO, and considering merging into a SPAC, or a reverse merger. For life sciences companies, reverse merger transactions have become a popular alternative approach to going public. Merging into a public life sciences company that has cash on hand and has experienced a failed clinical program raises a number of legal considerations. During this session, we will discuss:

  • How this differs from a reverse merger into a shell;
  • Structuring alternatives;
  • Documentation, process and timeline;
  • Addressing board and employee matters;
  • Anticipating litigation; and
  • Concurrent or subsequent financing opportunities.

CLE is not available when viewing a recording of this program. In order to receive credit you must have attended the live webinar program.

Resource Downloads

Stay Up To Date With Our Insights

See how we use a multidisciplinary, integrated approach to meet our clients' needs.